Feedback
Settings

Settings

Goto Application

1. WO2003037347 - STAUROSPORINE DERIVATIVES AS INHIBITORS OF FLT3 RECEPTOR TYROSINE KINASE ACTIVITY

PermaLink
Publication Number WO/2003/037347
Publication Date 08.05.2003
International Application No. PCT/EP2002/012076
International Filing Date 29.10.2002
Chapter 2 Demand Filed 29.03.2003
IPC
A61K 31/535 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
A61K 31/55 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/553 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
553having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
CPC
A61K 31/4015
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
4015having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
A61K 31/404
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403condensed with carbocyclic rings, e.g. carbazole
404Indoles, e.g. pindolol
A61K 31/407
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
407condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/535
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
A61K 31/55
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/553
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
553having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
Applicants
  • NOVARTIS AG [CH]/[CH] (AE, AG, AL, AM, AU, AZ, BA, BB, BE, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FR, GB, GD, GE, GH, GR, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MC, MD, MK, MN, MX, NL, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, UZ, VC, VN, YU, ZA, ZW)
  • NOVARTIS PHARMA GMBH [AT]/[AT] (AT)
  • DANA-FARBER CANCER INSTITUTE INC. [US]/[US] (AllExceptUS)
  • GRIFFIN, James, Douglas [US]/[US] (UsOnly)
  • MANLEY, Paul, William [GB]/[CH] (UsOnly)
Inventors
  • GRIFFIN, James, Douglas
  • MANLEY, Paul, William
Agents
  • GROS, Florent
Priority Data
60/338,18507.12.2001US
60/339,03130.10.2001US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) STAUROSPORINE DERIVATIVES AS INHIBITORS OF FLT3 RECEPTOR TYROSINE KINASE ACTIVITY
(FR) DERIVES DE STAUROSPORINE INHIBITEURS DE L'ACTIVITE TYROSINE KINASE DU RECEPTEUR FLT3
Abstract
(EN) The present invention relates to the use of staurosporines derivatives for the preparation of a drug for the treatment of diseases involving deregulated FLT3 receptor tyrosine kinase activity, especially for the curative and/or prophylactic treatment of leukemias and myelodysplastic syndromes, and to a method of treating diseases involving deregulated FLT3 receptor tyrosine kinase activity.
(FR) La présente invention concerne l'utilisation de dérivés de staurosporine dans la préparation d'un médicament administré dans le traitement des maladies associées à un déréglement de l'activité tyrosine kinase du récepteur FLT3, en particulier le traitement curatif et/ou prophylactique des leucémies et des syndromes myélodysplasiques, et une méthode de traitement des maladies associées à un déréglement de l'activité tyrosine kinase du récepteur FLT3.
Related patent documents
ES2269793
CN101703509
DE000060213842
PT1441737
KR1020090087139
EP1441737
RU02337692
US20050020570
CN1582150
CA2462657
AU2002357992
DK1441737
ID039.576
JP2005507412
BRPI0213739
PH1/2004/500601
PL211461
AT335490
SG2004017083
IL161156
ZA2004/02498
ZA200402498This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
NZ532136
KR1020050040842
MXPA/a/2004/004137
NO20042123This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
AU2006249245
US20110224194
US20120252785
Latest bibliographic data on file with the International Bureau
# -